TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,777,861 | -45.6% | 441,267 | -20.3% | 0.02% | -52.8% |
| Q1 2023 | $12,453,005 | +196.1% | 553,713 | +176.8% | 0.04% | +176.9% |
| Q4 2022 | $4,206,231 | +56.4% | 200,011 | +83.2% | 0.01% | +44.4% |
| Q3 2022 | $2,690,000 | -44.6% | 109,166 | -45.5% | 0.01% | -43.8% |
| Q2 2022 | $4,854,000 | -13.0% | 200,333 | -7.5% | 0.02% | 0.0% |
| Q1 2022 | $5,581,000 | +84.6% | 216,587 | +122.4% | 0.02% | +166.7% |
| Q4 2021 | $3,023,000 | +260.7% | 97,400 | +190.3% | 0.01% | +200.0% |
| Q1 2021 | $838,000 | -22.4% | 33,550 | -15.4% | 0.00% | -33.3% |
| Q4 2020 | $1,080,000 | – | 39,637 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |